{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:51:03Z","timestamp":1777639863538,"version":"3.51.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,14]]},"DOI":"10.1093\/eurheartj\/eht042","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T00:54:44Z","timestamp":1361408084000},"page":"1708-1713","source":"Crossref","is-referenced-by-count":154,"title":["Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy"],"prefix":"10.1093","volume":"34","author":[{"given":"Stefan","family":"Agewall","sequence":"first","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Oslo University, Oslo, Norway"}]},{"given":"M.","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Medicina 3, Ospedale San Paolo. Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milano, Milan, Italy"}]},{"given":"J.P.","family":"Collet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Pierre et Marie Curie-INSERM U 937 Institut de Cardiologie Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re (APHP) 47-83, Bd de l'hopital, 75013, Paris, France"}]},{"given":"F.","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Catholic University Hospital, Rome, Italy"}]},{"given":"G.Y.H.","family":"Lip","sequence":"additional","affiliation":[{"name":"University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom"}]},{"given":"F.W.A.","family":"Verheugt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands"}]},{"given":"K.","family":"Huber","sequence":"additional","affiliation":[{"name":"3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria"}]},{"given":"E.L.","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Skejby, Denmark"}]},{"given":"J.","family":"Morais","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar Leiria Pombal, Leiria, Portugal"}]},{"given":"S.","family":"Husted","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark"}]},{"given":"S.","family":"Wassmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Isar Heart Center, Isar Kliniken, Munich, Germany"}]},{"given":"G.","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana, 235 Roma, Italy"}]},{"given":"D.","family":"Atar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Oslo University, Oslo, Norway"}]},{"given":"A.","family":"Pathak","sequence":"additional","affiliation":[{"name":"CHU et Facult\u00e9 de M\u00e9decine de Toulouse, Institut des Maladies M\u00e9taboliques et Cardiovasculaires (U104), Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"}]},{"given":"K.","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"The Heart Centre, Copenhagen University Hospital (Rigshospitalet) and The Faculty of Medicine, Aalborg University, Copenhagen and Aalborg, Denmark"}]},{"given":"R.F.","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science, University of Sheffield, Sheffield, UK"}]},{"name":"on behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2013,2,20]]},"reference":[{"key":"key\n\t\t\t\t20180328144257_EHT042C1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328144257_EHT042C2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328144257_EHT042C3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","article-title":"ACCF\/ACG\/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use","volume":"56","author":"Abraham","year":"2010","journal-title":". J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C4","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazol on the antiplatelet action of clopidogrel associated to ASA","volume":"4","author":"Gilard","year":"2006","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328144257_EHT042C6","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in ASA treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328144257_EHT042C7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of ASA is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"W\u00fcrtz","year":"2010","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180328144257_EHT042C8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/FJC.0b013e3181af6d9c","article-title":"Do proton pump inhibitors attenuate the effect of ASA on platelet aggregation? A randomized crossover study","volume":"54","author":"Adamopoulos","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/003655200750024083","article-title":"Omeprazole does not interfere with the antiplatelet effect of low-dose ASA in man","volume":"35","author":"I\u00f1arrea","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180328144257_EHT042C11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2133\/dmpk.23.412","article-title":"Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine","volume":"23","author":"Hagihara","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"key\n\t\t\t\t20180328144257_EHT042C12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180328144257_EHT042C13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328144257_EHT042C14","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/CIRCULATIONAHA.109.873497","article-title":"Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome","volume":"120","author":"Rassen","year":"2009","journal-title":"Circulation."},{"key":"key\n\t\t\t\t20180328144257_EHT042C15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1160\/TH09-11-0800","article-title":"Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors","volume":"104","author":"Sarafoff","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1160\/TH10-04-0218","article-title":"Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation","volume":"104","author":"Tentzeris","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without Omeprazole in Coronary Artery Disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C18","article-title":"Gastrointestinal events with clopidogrel: a nationwide population-based cohort study","author":"Grove","year":"2012","journal-title":"J Gen Intern Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20180328144257_EHT042C20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archinternmed.2010.34","article-title":"Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor","volume":"170","author":"Stockl","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C21","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-funtion allele or proton pump inhibitor co-administration: A systematic meta-analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328144257_EHT042C24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":". N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0031-1296195","article-title":"Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor","volume":"61","author":"Seiler","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t20180328144257_EHT042C27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH11-09-0622","article-title":"Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel","volume":"107","author":"Aradi","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","article-title":"Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor","volume":"51","author":"Teng","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180328144257_EHT042C29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor\/clinical perspective","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328144257_EHT042C31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0248-8663(05)81200-7","article-title":"Omeprazole and liver functions","volume":"13","author":"Sauvet","year":"1992","journal-title":"Rev Med Interne"},{"key":"key\n\t\t\t\t20180328144257_EHT042C32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1620\/tjem.224.293","article-title":"The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin","volume":"224","author":"Jung","year":"2011","journal-title":"Tohoku J Exp Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C33","first-page":"260","article-title":"The absorption of warfarin from the rat stomach in situ","volume":"54","author":"Julkunen","year":"1976","journal-title":"Med Biol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1559-0275-8-12","article-title":"Drug metabolizing enzyme acitivites versus genetic variances for drug of clinical pharmacogenomic relevance","volume":"8","author":"Wu","year":"2011","journal-title":"Clin Proteomics"},{"key":"key\n\t\t\t\t20180328144257_EHT042C36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0044011-200929010-00004","article-title":"Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies","volume":"29","author":"Vakily","year":"2009","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t20180328144257_EHT042C37","first-page":"243","article-title":"Lack of pantoprazol drug interactions in man: an updated review","volume":"34","author":"Steinijans","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328144257_EHT042C38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.1999.00021.x","article-title":"Review article: drug interactions with agents used to treat acid-related diseases","volume":"13","author":"Humphries","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328144257_EHT042C39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2011.08633.x","article-title":"Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment","volume":"153","author":"Teichert","year":"2011","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C40","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C41","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C42"},{"key":"key\n\t\t\t\t20180328144257_EHT042C43","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C44","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328144257_EHT042C45"},{"key":"key\n\t\t\t\t20180328144257_EHT042C46","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Baursachs","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C48","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328144257_EHT042C50","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2000.00788.x","article-title":"Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors","volume":"14","author":"Stedman","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328144257_EHT042C51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2011.04707.x","article-title":"Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using ASA for secondary prevention","volume":"34","author":"Saini","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328144257_EHT042C52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amjcard.2010.08.067","article-title":"Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation","volume":"107","author":"Rossini","year":"2011","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328144257_EHT042C53","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/23\/1708\/17895194\/eht042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T16:47:29Z","timestamp":1522255649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/34\/23\/1708\/425272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,20]]},"references-count":53,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2013,2,20]]},"published-print":{"date-parts":[[2013,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht042","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,6,14]]},"published":{"date-parts":[[2013,2,20]]}}}